Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Evofem Biosciences Inc (EVFM)

Evofem Biosciences Inc (EVFM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 1,520
  • Shares Outstanding, K 126,686
  • Annual Sales, $ 19,360 K
  • Annual Income, $ -8,860 K
  • EBIT $ 0 M
  • EBITDA $ 0 M
  • 60-Month Beta -1.28
  • Price/Sales 0.09
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.06
  • Most Recent Earnings $-0.01 on 11/13/25
  • Next Earnings Date 03/23/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0085 +30.59%
on 11/20/25
0.0136 -18.38%
on 12/12/25
+0.0021 (+23.33%)
since 11/14/25
3-Month
0.0080 +38.75%
on 11/06/25
0.0200 -44.50%
on 10/27/25
-0.0041 (-26.97%)
since 09/15/25
52-Week
0.0061 +81.97%
on 02/27/25
0.0200 -44.50%
on 10/27/25
+0.0014 (+14.43%)
since 12/13/24

Most Recent Stories

More News
Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE

— PHEXX ® Poised to Become First and Only  Hormone-Free Contraceptive Vaginal Gel Approved in UAE —

EVFM : 0.0111 (-7.50%)
Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update

-- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --

EVFM : 0.0111 (-7.50%)
Evofem Announces Voting Results from Special Meeting of Stockholders

-- Evofem Shareholders Did Not Approve the Merger with Aditxt --

EVFM : 0.0111 (-7.50%)
ADTX : 1.44 (-35.71%)
Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates

— First ex-U.S. Regulatory Filing for SOLSOEC ® —

EVFM : 0.0111 (-7.50%)
Evofem Biosciences Honors World Contraception Day

SAN DIEGO , Sept. 26, 2025 /PRNewswire/ -- On World Contraception Day, Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCID: EVFM) honors the millions of people worldwide who rely...

EVFM : 0.0111 (-7.50%)
Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms

-- 130% increase in traffic to PHEXXI.com, the website for Evofem's hormone-free prescription contraceptive PHEXXI ® (lactic acid citric acid and potassium bitartrate) --

EVFM : 0.0111 (-7.50%)
ADTX : 1.44 (-35.71%)
Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

-- Special Meeting to be held on September 26, 2025 --

EVFM : 0.0111 (-7.50%)
ADTX : 1.44 (-35.71%)
Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law

-- Passage of House Bill 3489 allows Illinois pharmacists to prescribe non-hormonal and emergency contraceptives --

EVFM : 0.0111 (-7.50%)
ADTX : 1.44 (-35.71%)
FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

-- Evofem now holds eleven Orange Book - listed patents covering SOLOSEC into late 2041 --

EVFM : 0.0111 (-7.50%)
Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

-- Increased Net Sales and Improved Loss from Operations in Q2 2025 vs. Prior Year Quarter --

EVFM : 0.0111 (-7.50%)

Business Summary

Evofem Biosciences Inc. develops and anticipates commercializing products which support and promote women as the primary healthcare consumer. The company is identifying and developing new and novel products which specifically address unmet needs in the areas of sexual and reproductive health, the prevention...

See More

Key Turning Points

3rd Resistance Point 0.0138
2nd Resistance Point 0.0129
1st Resistance Point 0.0120
Last Price 0.0111
1st Support Level 0.0102
2nd Support Level 0.0093
3rd Support Level 0.0084

See More

52-Week High 0.0200
Fibonacci 61.8% 0.0147
Fibonacci 50% 0.0130
Fibonacci 38.2% 0.0114
Last Price 0.0111
52-Week Low 0.0061

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar